Generic prescription drug price increases: which products will be affected by proposed anti-gouging legislation?

Table 1 Drug Price Increase “Hot Spots”^a

Price Change Distribution, Measured at the Drug Level	2013-2014
Price Change Distribution, Measured at the Drug Level	Overall	% > Medical CPI	% > 15%	% > 20%
Number of Unique Molecules in Sample	2,285	1,648	987	826
Molecule-Seller-Formulation Combinations in Sample	6,182	3,102	1,713	1,425
Percentage of Molecule-Seller-Formulation Combinations Meeting Threshold	-	50%	28%	13%
Number of Manufacturers in Sample	378	319	213	197
Percentage of total manufacturers producing molecules meeting threshold	-	84%	56%	52%
Quarterly Use (millions of units)
Mean	7.83	7.03	7.49	7.94
Standard Deviation	3.48	3.67	2.62	2.76
Quarterly Sales (millions of dollars)
Average	3.66	3.78	3.53	2.83
Standard Deviation	1.73	2.01	1.71	1.13
Price Change
Mean	38%	93%	162%	191%
Median	2%	17%	41%	52%
95th Percentile	135%	249%	376%	424%
Standard Deviation	1053%	1485%	1995%	2187%
Price Level, 2013 ($)
Average	29.69	43.35	30.72	22.63
Standard Deviation	378.44	521.16	385.12	292.56
Hot Spot Market Share^b
Based on Total Extended Units Sold	-	45%	27%	23%
Based on Total Inflation-Adjusted Sales	-	25%	12%	8%

^aAuthors’ calculations using IQVIA Health NSP data. All analyses used STATA 14.0 (College Station, Texas)
^bHot Spot market share was calculated in terms of total extended units (total extended units sold by hot spot products divided by total extend units sold of all products) and total inflation-adjusted sales (total inflation-adjusted sales of products by hot spot products divided by total inflation-adjusted sales of all products) by era

ISSN: 2052-3211